Pulmonary Fibrosis News and Research

RSS

InterMune reaches definitive agreement with Vidara to sell Actimmune

InterMune, Inc. today announced that it has reached a definitive agreement with Vidara Therapeutics International Limited (Vidara) to sell its rights to Actimmune (interferon gamma-1b) in a cash transaction valued at $55 million plus a two-year royalty stream.

22 May 2012

Osteopenia/osteoporosis more prevalent among male patients with pulmonary disease

There is a very high prevalence of osteopenia/osteoporosis among male patients with pulmonary disease, according to a new study from researchers in California.

21 May 2012

Three-drug combo harmful for patients with idiopathic pulmonary fibrosis

A combination of three drugs used worldwide as the standard of care for a serious lung disease puts patients in danger of death or hospitalization, and should not be used together to treat the disease, called idiopathic pulmonary fibrosis, according to the surprising results of a rigorous independent study.

21 May 2012

African-Americans with scleroderma have more antibodies linked to severe complications

A new analysis finds that compared to Caucasians, African-Americans with systemic scleroderma have more antibodies in the blood that are linked to severe complications and an increased likelihood of death. They say this finding, published today in Arthritis & Rheumatism, suggests physicians can use these disease markers to screen and treat scleroderma patients proactively.

11 May 2012

African Americans have more severe complications from scleroderma

African Americans have more severe complications from systemic sclerosis, also known as scleroderma, than Caucasians. Findings published today in, Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR), show that compared with Caucasians, African-American patients were more likely to have antibodies that increased frequency and severity of pulmonary fibrosis, which is associated with decreased survival.

10 May 2012

Comorbidities common among patients with COPD

Comorbidities are common among patients with chronic obstructive pulmonary disease (COPD), and a number of these comorbidities are independently associated with an increased mortality risk, according to a new study.

4 May 2012

Biogen Idec first quarter revenues increase 7% to $1.3 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its first quarter 2012 results.

2 May 2012

UMKC School of Medicine receives $400,000 gift to establish Pulmonary Fibrosis Research Program

The University of Missouri-Kansas City has received a $400,000 gift to establish a pulmonary fibrosis research program at the UMKC School of Medicine. The gift comes from the estate of the late Mary K. Geldmacher, a retired St. Louis school teacher who suffered from pulmonary fibrosis and passed away in 2009. Pulmonary fibrosis is the formation or development of excess fibrous connective tissue in the lungs, commonly described as “scarring of the lung.”

26 Apr 2012

UT Southwestern lung transplant recipient lives through 19 years

UT Southwestern Medical Center has performed more than 300 lung transplants in recent decades, and Michael Young represents a remarkable success story.

25 Apr 2012

CLYD gene serves as crucial negative regulator in pulmonary fibrosis

An international team of researchers led by Georgia State University scientists have found a key component in the pathological process of pulmonary fibrosis, a fatal disease for which there is currently no cure.

11 Apr 2012

CPF proclaims September as 'Pulmonary Fibrosis Awareness Month'

The Coalition for Pulmonary Fibrosis (CPF) announced today the month of September 2012 will be proclaimed "Pulmonary Fibrosis Awareness Month." In previous years, the CPF has celebrated "National Pulmonary Fibrosis Awareness Week" for one week each September, but expanding the time frame to a month will help achieve greater national awareness and fundraising in the race to find treatment and a cure.

7 Apr 2012

Experts highlight latest advances in use of biomarkers in various diseases

Over the last few decades there has been an explosion in the discovery of biomarkers for diagnosis, disease monitoring, and prognostic evaluation. In the April issue of Translational Research, entitled "Biomarkers: New Tools of Modern Medicine," an international group of medical experts explores the promise and challenges of biomarker discovery and highlights the latest advances in the use of biomarkers in various diseases.

16 Mar 2012

Inhaled interferon-gamma may effectively treat IPF

Inhaled interferon-gamma may be an effective treatment for idiopathic pulmonary fibrosis (IPF), a chronic and progressive form of lung disease caused by excessive formation of fibrotic, or scar tissue, in the lungs, according to an article published in Journal of Aerosol Medicine and Pulmonary Drug Delivery, a peer-reviewed journal from Mary Ann Liebert, Inc.

1 Mar 2012

DTMI, Bristol-Myers Squibb partner to broaden interactions

Bristol-Myers Squibb Company and Duke Translational Medicine Institute (DTMI) today announced the formation of a strategic relationship to broaden interactions between the two organizations.

28 Feb 2012

Statin use may influence susceptibility to ILD in smokers

Use of statins may influence susceptibility to or the progression of interstitial lung disease (ILD) in smokers, according to a new study.

6 Jan 2012

IQWiG examines added benefit of pirfenidone for idiopathic pulmonary fibrosis

Pirfenidone inhibits the development of inflammation and scarring (fibrosis) in pulmonary tissue and has been approved for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) since the beginning of 2011.

4 Jan 2012

IQWiG publishes report on Esbriet benefit assessment for treatment of IPF

InterMune, Inc. today reported that the private Institute for Quality and Efficiency in Health Care (IQWiG) has today published its report on the benefit assessment of Esbriet (pirfenidone) for the treatment of mild to moderate idiopathic pulmonary fibrosis.

16 Dec 2011